The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh Impact•24 February 2026•

1 min read

Travere Therapeutics Reports Strong FY25 Growth and Profitability Ahead of FDA Decision

Key Facts

1Travere's FY25 revenue reached $410.5M, an 81% year-over-year increase.

2FILSPARI sales grew 144% YoY, driven by record patient starts.

Travere Therapeutics (TVTX) reported a standout fiscal year 2025, with total revenue surging 81% year-over-year to reach $410.5 million. The growth was primarily fueled by the commercial success of FILSPARI, which saw sales jump 144% alongside record levels of new patient starts. Significantly, the company achieved a major milestone by turning profitable in the fourth quarter, posting a non-GAAP net income of $81.1 million. This financial turnaround reflects both strong market demand and improved cost discipline across the organization. Investors are now shifting their focus toward April, when a critical FDA PDUFA decision regarding the FSGS treatment is expected. This upcoming regulatory catalyst, combined with solid fundamental growth, positions the biotech firm for a potentially transformative year.